The median survival of patients with platinum sensitive recurrent ovarian cancer is estimated to be 2 years, but it can range from only a few months to more than a decade. Patients who relapse within 6 months of completing first-line therapy have been classified as being “platinum resistant”...
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302–8. Article CAS PubMed Google Scholar Chen V, Umemura S, Han Y, Raman R, Tucker R, Chahine J, et al. Exploiting ...
platinum-resistant recurrent EOC remains largely unclear.AIM To evaluate the feasibility of secondary cytoreductive surgery for treating platinum-resistant recurrent EOC.METHODS This was a retrospective study of the clinical data of patients with platinumresistant EOC admitted to the Cancer Hospital of the...
Treatment of platinum-resistant recurrent ovarian cancer using a "predictive molecule targeted routine chemotherapy" systemof,a,帮助,using,Using 文档格式: .pdf 文档大小: 537.07K 文档页数: 5页 顶/踩数: 0/0 收藏人数: 0 评论次数: 0 文档热度: ...
Bevacizumab is an antiangiogenic agent that was approved in 2014 for the treatment of women with platinum-resistant, recurrent ovarian cancer. The approval was based the phase III AURELIA trial that randomized individuals to receive physician’s choice of chemotherapy or chemotherapy with bevacizumab, ...
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. In platinum-resistant ovarian cancer (OC), single-agent chemotherapy is standard. Bevacizumab is active alone and in combination. AURELIA is the first rand......
The combination of the novel adoptive natural killer-like T (NK-T) cell therapy CRX100 with oncolytic vaccinia virus demonstrated tolerability and conferred responses in a small cohort of patients with recurrent platinum-resistant ovarian cancer, according to findings from a phase 1 trial (NCT042820...
The objective was to determine the response rate to platinum retreatment of "platinum-resistant" ovarian cancer after intervening nonplatinum therapy. We retrospectively identified 30 patients with platinum-resistant ovarian cancer who received nonplatinum chemotherapy for recurrent epithelial ovarian cancer pr...
Conclusions: Conclusions Anlotinib plus letrozole showed a promising efficacy with a favorable toxicity profile for patients with platinum-resistant recurrent ovarian cancer. The trial is ongoing and more data will be provided in the future. Clinical trial information: NCT04720807....
Christina Buschmann1, Susanne Beyer1, Thomas Kolben1, Fabian Kraus1, Anca Chelariu‑Raicu1, Alexander Burges1, Sven Mahner1, Udo Jeschke1,3, Fabian Trillsch1 & Bastian Czogalla1* In recurrent epithelial ovarian cancer (EOC) most patients develop platinum-resistance. ...